Progress Report: Sri Lanka Clinical Trials Registry

At completion 1. Baseline data Any changes to the trial design/ methodology/ protocol after commencement: Sample size was changed from 60 to 30 Any changes to trial outcomes after commencement: No 2. Current status Recruitment status: Pending Number assessed for eligibility:21 Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA Please attach a scanned copy or link to paper)			
Date: 05 01 02 03 03 05 04 05 04 04 05 04 04	SLCTR registration number: SLCTR/2016/0	001	
At completion 1 year 2 years 3 years 4 At completion 4 1. Baseline data Any changes to the trial design/ methodology/ protocol after commencement: Sample size was changed from 60 to 30 Any changes to trial outcomes after commencement: No 2. Current status Recruitment status: Pending Number assessed for eligibility:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA Please attach a scanned copy or link to paper)	Scientific title of trial: A study to determine oral N-Acetylcysteine and methionine amount	the palatability of difference ng healthy volunteers	ent dosage forms of
At completion 1. Baseline data Any changes to the trial design/ methodology/ protocol after commencement: Sample size was changed from 60 to 30 Any changes to trial outcomes after commencement: No 2. Current status Recruitment status: Pending Number assessed for eligibility:21 Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications: NA Please attach a scanned copy or link to paper)	Date of commencement (enrolment of first	participant):21/04/2106	
Any changes to the trial design/ methodology/ protocol after commencement: Sample size was changed from 60 to 30 Any changes to trial outcomes after commencement: No 2. Current status Recruitment status: Pending Number assessed for eligibility:21 Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA Please attach a scanned copy or link to paper)	Progression: 6 months 1 year	□ 2 years □	3 years □
Any changes to the trial design/ methodology/ protocol after commencement: Sample size was changed from 60 to 30 Any changes to trial outcomes after commencement: No 2. Current status Recruitment status: Pending Number assessed for eligibility:21 Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications: NA Please attach a scanned copy or link to paper)	At completion		
Any changes to trial outcomes after commencement: No 2. Current status Recruitment status: Pending Number assessed for eligibility:21 Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA Please attach a scanned copy or link to paper)	1. Baseline data		
Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to paper) Date: 05/01/2	Any changes to the trial design/ methodolo size was changed from 60 to 30	ogy/ protocol after comme	encement: Sample
Recruitment status: Pending Number assessed for eligibility:21 Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA Please attach a scanned copy or link to paper)	Any changes to trial outcomes after comme	encement: No	
Number assessed for eligibility:21 Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA Please attach a scanned copy or link to paper)	2. Current status		
Number recruited and randomized:21 Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications: NA Please attach a scanned copy or link to paper)	Recruitment status: Pending		
Number allocated to each intervention/arm:21 Losses/exclusions after randomization:7 3. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA (Please attach a scanned copy or link to paper)	Number assessed for eligibility:21		
A. Trial output Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications:NA Please attach a scanned copy or link to paper)	Number recruited and randomized:21		
Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications: NA (Please attach a scanned copy or link to paper) Date: 05/01/2	Number allocated to each intervention/arm	:21	
Summary of Interim/Final data (if available): NA Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications: NA Please attach a scanned copy or link to paper) Date: 05/01/2	Losses/exclusions after randomization:7		
Presentations of results at scientific meetings: NA (Please attach a scanned copy or link to abstract) Publications: NA Please attach a scanned copy or link to paper) Date: 05/01/2	3. Trial output		
(Please attach a scanned copy or link to abstract) Publications: NA Please attach a scanned copy or link to paper) Date: 05/01/2	Summary of Interim/Final data (if available	e): NA	
Publications: NA Please attach a scanned copy or link to paper) Date: 05/01/2	Presentations of results at scientific meetin	gs: NA	
Please attach a scanned copy or link to paper) Date: 05/01/2	(Please attach a scanned copy or link to at	ostract)	
Date: 05/01/2	Publications:NA (Please attach a scanned copy or link to pa	per)	
Date: 05/01/2			
	Drof I D. Company		Date: 05/01/2

Prof. Indika Gawarammana (MBBS, MD, MRCP, FRCPE, PhD) Consultant Physician - Teaching Hospital Peradeniya Professor - Department of Medicine, Faculty of Medicine University of Peradeniya.